Program

Icon Legend

Presentation Icons

CME

Non-CME

ISS CME

Named Award Winner

Award Winner

Poster Award Winner

Type here to filter the list

Friday, Nov 17th
7:15 AM – 7:25 AM PT
CTIM-18 - NRG Oncology Study BN007: Randomized phase II/III trial of ipilimiumab (Ipi) plus nivolumab (Nivo) vs. temozolomide (TMZ) in MGMT-unmethylated (uMGMT) newly diagnosed glioblastoma (nGBM)
Location: Room 109-110
Oral Abstract Presenter: Andrew B. Lassman – Columbia University Vagelos College of Physicians and Surgeons and New York Presbyterian Hospital
Author: Mei-Yin C. Polly – NRG Oncology Statistics and Data Management Center
Author: Fabio M. Iwamoto – Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center
Author: Andrew E. Sloan – Piedmont Health
Author: Tony JC Wang – Division of Department of Radiation Oncology (in Neurological Surgery) and Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian
Author: Kenneth D. Aldape – Laboratory of Pathology, National Cancer Institute, NIH
Author: Jeffrey S. Wefel – The University of Texas MD Anderson Cancer Center
Author: Vinai Gondi – Northwestern Medicine Cancer Center Warrenville
Author: Alonson N. Gutierrez – Miami Cancer Institute
Author: Mohammed Manasawala – WellSpan Health-York Cancer Center
Author: Mark R. Gilbert – National Cancer Institute, National Institutes of Health
Author: Erik P. Sulman – New York University Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
Author: Jedd D. Wolchok – Meyer Cancer Center, Weill Cornell Medicine
Author: Richard M. Green – Kaiser Permanente-Los Angeles Medical Center, Accrual for Kaiser Permanente NCI Community Oncology Research Program
Author: Elizabeth C. Neil – M Health Fairview Cancer Center, Accruals for Metro Minnesota Community Oncology Research Consortium
Author: Rimas V. Lukas – Department of Neurology, Northwestern University
Author: Samuel A. Goldlust – Saint Luke’s Marion Bloch Neuroscience Institute
Author: Matija Snuderl – New York University
Author: James Dignam – NRG Oncology Statistics and Data Management Center
Author: Minhee Won – NRG Oncology Statistics and Data Management Center
Author: Benjamin Movsas – Henry Ford Hospital
Author: Minesh P. Mehta – Miami Cancer Institute
Clinical trials: Immunologic
Friday, Nov 17th
7:25 AM – 7:35 AM PT
CTIM-14 - Phase 1 safety lead-in and randomized open-label perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1-mutant astrocytomas: safety lead-in results
Location: Room 109-110
Oral Abstract Presenter: Patrick Y. Wen – Dana-Farber Cancer Institute
Author: Katherine B. Peters – Duke University Medical Center
Author: Macarena I. de la Fuente – Sylvester Comprehensive Cancer Center
Author: Ingo K. Mellinghoff – Memorial Sloan Kettering Cancer Center
Author: Isabel Arrillaga-Romany – Massachusetts General Hospital
Author: Priya U. Kumthekar – Northwestern University
Author: Jennifer L. Clarke – University of California San Francisco
Author: Vinay K. Puduvalli – University of Texas MD Anderson Cancer Center
Author: John F. de Groot – University of California, San Francisco
Author: Xiangmin Zhang – Servier Pharmaceuticals
Author: Michael Chisamore – Merck & Co., Inc.
Author: Michelle Abshire – Servier Pharmaceuticals
Author: Paria Mahboub – Servier Pharmaceuticals
Author: Islam Hassan – Servier Pharmaceuticals
Author: Jeffrey Knipstein – Servier Pharmaceuticals
Author: Timothy F. Cloughesy – University of California Los Angeles
Clinical trials: Immunologic
Friday, Nov 17th
7:35 AM – 7:45 AM PT
CTIM-09 - Phase 1/1b trial of Fc-engineered Anti-CD40 Agonist Monoclonal Antibody (2141-V11) infused with D2C7-IT in enhancing disease by Convection-Enhanced Delivery (CED) for Recurrent Malignant Glioma (rMG)
Location: Room 109-110
Oral Abstract Presenter: Annick Desjardins – Duke University
Author: Vidya Chandramohan – Duke University
Author: Daniel B. Landi – Duke University
Author: Katherine B. Peters – Duke University Medical Center
Author: Margaret O. O. Johnson – Duke University School of Medicine, The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
Author: Justin T. Low – Duke University School of Medicine
Author: Mustafa Khasraw – Duke Cancer Institute
Author: Stevie Threatt – Duke University Medical Center
Author: Chevelle Bullock – Duke University Medical Center
Author: James E. Herndon, II – Duke Cancer Institute, Department of Biostatistics
Author: Eric S. Lipp – The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
Author: Allan H. Friedman – Department of Neurosurgery, Duke University
Author: Henry S. Friedman – The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
Author: David M. Ashley – The Preston Robert Tisch Brain Tumor Center
Author: Juan Osorio – The Rockefeller University
Author: Jeffrey Ravetch – The Rockefeller University
Author: Darell D. Bigner – Duke University
Clinical trials: Immunologic
Friday, Nov 17th
7:45 AM – 7:55 AM PT
CTIM-19 - Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Location: Room 109-110
Oral Abstract Presenter: Farshad Nassiri – University of Toronto
Author: Vikas Patil – UHN
Author: Leeor S. Yefet – Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada
Author: Olivia Singh – Princess Margaret Cancer Research Tower
Author: Jeff Liu – University of Toronto
Author: Rachel Dang – Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA
Author: Takafumi Yamaguchi – Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA
Author: Mariza Daras – University of California San Francisco
Author: Timothy F. Cloughesy – University of California Los Angeles
Author: Howard Colman – Huntsman Cancer Institute, University of Utah
Author: Priya U. Kumthekar – Northwestern University
Author: Clark C. Chen – University of Minnesota
Author: Robert Aiken – Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA
Author: Morris D. Groves – Department of Neurology, Texas Oncology, Austin, TX, USA
Author: Shirley S. Ong – Division of Neuro-Oncology, Department of Neurology, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA
Author: Rohan Ramakrishna – Cornell University Weill Medical Center
Author: Michael A. A. Vogelbaum – Department of NeuroOncology, Moffitt Cancer Center
Author: Simon Khagi – Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Author: Thomas Kaley – Memorial Sloan Kettering Cancer Center
Author: Jason Melear – Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA
Author: David M. Peereboom – Cleveland Clinic, Ohio
Author: Analiz Rodriguez – University of Arkansas for Medical Sciences
Author: Maxim Yankelevich – St. Christopher's Hospital for Children
Author: Suresh Nair – Lehigh Valley Topper Cancer Institute, Allentown, PA, USA
Author: Vinay K. Puduvalli – University of Texas MD Anderson Cancer Center
Author: Kenneth D. Aldape – Laboratory of Pathology, National Cancer Institute, NIH
Author: Andrew Gao – Princess Margaret Cancer Research Tower
Author: Alvaro Lopez-Janeiro – Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain Navarra Institute for Health Research (IdISNA), Pamplona, Spain
Author: Carlos de Andrea – Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain Navarra Institute for Health Research (IdISNA), Pamplona, Spain
Author: Marta Alonso – Navarra Institute for Health Research (IdISNA), Pamplona, Spain Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain Program of Solid Tumors, Center for the Applied Medical Research (CIMA), Pamplona, Spain
Author: Paul Boutros – Navarra Institute for Health Research (IdISNA), Pamplona, Spain Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain Program of Solid Tumors, Center for the Applied Medical Research (CIMA), Pamplona, Spain
Author: Joan Robbins – DNATrix Inc., Carlsbad, CA, USA
Author: Warren P. Mason – Princess Margaret Cancer Centre
Author: Adam M. Sonabend – Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Author: Roger Stupp – Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Author: Juan Fueyo-Margareto – MD Anderson
Author: Candelaria Gomez-Manzano – MD Anderson
Author: Frederick F. Lang – MD Anderson
Author: Gelareh Zadeh – University Health Network, Toronto Western Hospital
Clinical trials: Immunologic
Friday, Nov 17th
7:55 AM – 8:05 AM PT
CTIM-20 - Systemic immune correlates associated with long-term survival after Therapeutic Adenovirus (DNX2401) plus Interferon gamma for Recurrent Glioblastoma Effect Trial (TARGET): a randomized phase 1 trial.
Location: Room 109-110
Oral Abstract Presenter: Chibawanye Ene – MD Anderson Cancer Center
Author: Sanjay K. Singh – MD Anderson
Author: Lynette Phillips – MD Anderson
Author: Raja Venkataraman – Johns Hopkins University
Author: Vinay K. Puduvalli – University of Texas MD Anderson Cancer Center
Author: Deep Singh – Alycyone therapeutics
Author: Nam Tram – Moffitt Cancer Center
Author: James Long – MD Anderson
Author: Martin Brady – Therataxis
Author: Raghu Raghavan – Therataxis
Author: Frank Tufaro – Theriva therapeutics
Author: Brett Ewald – MD Anderson
Author: PJ Anand – Alycyone therapeutics
Author: J. Bradley B. Elder – Ohio State University
Author: Karen L. Fink – Baylor Scott and White
Author: W.K. Alfred Yung – University of Texas MD Anderson Cancer Center
Author: Marta Penas-Prado – National Cancer Insitute, National Institutes of Health
Author: Nick Navin – MD Anderson
Author: Benjamin Larman – Johns Hopkins University
Author: Candelaria Gomez-Manzano – MD Anderson
Author: Juan Fueyo-Margareto – MD Anderson
Author: Joanna Peterkin – Therataxis
Author: Frederick F. Lang – MD Anderson
Clinical trials: Immunologic
Friday, Nov 17th
8:05 AM – 8:15 AM PT
CTIM-06 - A Phase 2 Study of a Novel Immunotherapy SL-701 in Adults With Recurrent Glioblastoma: Exploring the Prognostic Value of Treatment-Induced CD8+CD57+ T-cells as a Marker for Survival.
Location: Room 109-110
Oral Abstract Presenter: David M. Peereboom – Cleveland Clinic, Ohio
Author: Ross W. Lindsay – Menarini Stemline
Author: Michael A. Badruddoja – Center for Neurosciences
Author: L. Burt Nabors – University of Alabama at Birmingham
Author: Priya U. Kumthekar – Northwestern University
Author: Frank S. Lieberman – University of Pittsburg
Author: David Schiff – University of Virginia School of Medicine
Author: Jonathan H. Sherman – University of West Virginia
Author: Nicholas A. Butowski – University of California San Francisco
Author: Erin M. Dunbar – Piedmont Healthcare
Author: Karen L. Fink – Baylor Scott and White
Author: Fabio M. Iwamoto – Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center
Author: Christopher L. Moertel – University of Minnesota Masonic Children's Hospital
Author: Michael Schulder – Northwell Health at North Shore University Hospital
Author: Tobias Walbert – Henry Ford Health
Author: Pratip Chattopadhyay – Talon Biomarkers
Author: Nassir Habboubi – Menarini Stemline
Author: Krzysztof J. Grzegorzewski – Menarini Stemline
Author: Christopher L. Brooks – Menarini Stemline
Author: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Clinical trials: Immunologic
Friday, Nov 17th
8:15 AM – 8:20 AM PT
CTIM-22 - Phase I study results of the antibody-cytokine fusion protein L19TNF in combination with lomustine for patients with recurrent glioblastoma reveal promising safety and durable tumor responses
Location: Room 109-110
Oral Abstract Presenter: Tobias Weiss – Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
Author: Emanuele Puca – Philogen S.p.A.,
Author: Alfredo Covelli – Philogen S.p.A.,
Author: Dorothee Gramatzki – Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland
Author: Patrick Roth – Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
Author: Dario Neri – Philogen S.p.A.,
Author: Teresa Hemmerle – Philogen S.p.A.,
Author: Michael Weller – Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
Clinical trials: Immunologic
Friday, Nov 17th
8:20 AM – 8:25 AM PT
CTIM-13 - Phase I clinical trial of oncolytic HSV-1 M032, a second-generation virus armed to expressed IL-12, for the treatment of adult patients with recurrent or progressive malignant glioma.
Location: Room 109-110
Oral Abstract Presenter: Dagoberto Estevez-Ordonez – University of Alabama Birmingham Neurosurgery
Author: John Stein – UAB
Author: Pedram Maleknia – UAB
Author: Carlos Gallegos – UAB
Author: Travis Atchley – UAB
Author: Nicholas Laskay – UAB
Author: Jennifer Clements – UAB
Author: Mina Lobbous – Cleveland Clinic Case Western Reserve University
Author: Jianmei Leavenworth – UAB
Author: Kristen Riley – UAB
Author: Inmaculada Aban – UAB
Author: Anna Sorace – UAB
Author: Rati Chkheidze – UAB
Author: Burt Nabors – Heersink School of Medicine
Author: James M. Markert – UAB
Clinical trials: Immunologic
Friday, Nov 17th
8:25 AM – 8:30 AM PT
CTIM-26 - Impact on survival of interferon-alpha delivery in glioblastoma with unmethylated MGMT by immuno-gene therapy with Temferon
Location: Room 109-110
Oral Abstract Presenter: Gaetano Finocchiaro – San Raffaele Hospital
Author: Valeria Cuccarini – Istituto Neurologico Carlo Besta
Author: Bernhard Gentner – San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Author: Alessia Capotondo – San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Author: Francesca Farina – San Raffaele Hospital
Author: Matteo Maria Naldini – San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Author: Matteo Barcella – San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Author: Elena Anghileri – Istituto Neurologico Carlo Besta
Author: Maria Grazia Bruzzone – Istituto Neurologico Carlo Besta
Author: Matteo Carrabba – San Raffaele Hospital
Author: Quintino Giorgio D'Alessandris – UOC Neurochirurgia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore
Author: Francesco Di Meco – Istituto Neurologico Carlo Besta
Author: Valeria Ferla – San Raffaele Hospital
Author: Alberto Franzin – Fondazione Poliambulanza
Author: Paolo Ferroli – Istituto Neurologico Carlo Besta
Author: Filippo Gagliardi – San Raffaele Hospital
Author: Federico Legnani – Istituto Neurologico Carlo Besta
Author: Stefania Mazzoleni – Genenta Science
Author: Pietro Mortini – Istituto Neurologico Carlo Besta
Author: Alessandro Olivi – UOC Neurochirurgia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore
Author: Roberto Pallini – Policlinico Gemelli
Author: Monica Patanè – Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Author: Rosina Paterra – Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Author: Bianca Pollo – Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Author: Marco Saini – Istituto Neurologico Carlo Besta
Author: Silvia Snider – San Raffaele Hospital
Author: Karen Mullen – Genenta Science
Author: Luigi Naldini – San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Author: Carlo Russo – Genenta Science
Author: Fabio Ciceri – San Raffaele Hospital
Author: Marica Eoli – Fondazione IRCCS Carlo Besta
Clinical trials: Immunologic
Friday, Nov 17th
8:30 AM – 8:35 AM PT
CTIM-23 - Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma
Location: Room 109-110
Oral Abstract Presenter: Shiao-Pei Weathers – University of Texas MD Anderson Cancer Center
Author: Carlos Kamiya-Matsuoka – MD Anderson Cancer Center
Author: Nazanin K. Majd – University of Texas MD Anderson Cancer Center
Author: Alda Ashu – University of Texas MD Anderson Cancer Center
Author: Chantell Thompson – University of Texas MD Anderson Cancer Center
Author: Evguenia Gachimova – University of Texas MD Anderson Cancer Center
Author: Ashley E. Aaroe – University of Texas MD Anderson Cancer Center
Author: Chirag B. Patel – University of Texas MD Anderson Cancer Center
Author: Monica Loghin – University of Texas MD Anderson Cancer Center
Author: Barbara J. O'Brien – University of Texas MD Anderson Cancer Center
Author: W.K. Alfred Yung – University of Texas MD Anderson Cancer Center
Author: Vinay K. Puduvalli – University of Texas MD Anderson Cancer Center
Author: John F. de Groot – University of California, San Francisco
Clinical trials: Immunologic
Friday, Nov 17th
8:35 AM – 8:40 AM PT
CTIM-25 - EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study (NCT04116658)
Location: Room 109-110
Oral Abstract Presenter: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Ahmed Idbaih – Sorbonne Université, AP-HP, ICM, Hôpital Universitaire La Pitié-Salpêtrière
Author: Maria Vieito – Hospital Universitari Vall d'Hebron
Author: François Ghiringhelli – Centre Georges-François Leclerc
Author: Agostina Stradella – Institut Catala D'Oncologia - Hospital Duran i Reynals
Author: Ghazaleh Tabatabai – University Hospital Tübingen and Eberhard Karls University Tübingen
Author: Michael C. Burger – Dr Senckenberg Institute of Neurooncology, Goethe University Hospital
Author: Iris Mildenberger – Medizinische Fakultät Mannheim
Author: Ulrich Herrlinger – Division of Clinical Neurooncology, Department of Neurology and Center for Integrated Oncology, University Hospital Bonn, Bonn, Germany
Author: Patrick Y. Wen – Dana-Farber Cancer Institute
Author: Mehdi Touat – Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) Sorbonne Université
Author: Antje Wick – Universitätsklinikum Heidelberg
Author: Macarena González – Hospital Universitari Vall d'Hebron
Author: Alice Hervieu – Centre Georges-François Leclerc
Author: Marta GilMartin – Institut Catala D'Oncologia - Hospital Duran i Reynals
Author: Mirjam Renovanz – Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research
Author: Cécile Gouttefangeas – Department of Immunology, Eberhard-Karls-University Tübingen
Author: Ana Maia – Department of Immunology, Eberhard-Karls-University Tübingen
Author: Christophe Bonny – Enterome
Author: Jean-Michel Paillarse – Enterome
Author: Laurent Chêne – Enterome
Author: Jan Fagerberg – Enterome
Author: Wolfgang Wick – Universitatsklinikum Heidelberg
Clinical trials: Immunologic
Friday, Nov 17th
3:10 PM – 3:20 PM PT
CTIM-37 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (PCNSL and SCNSL)
Location: Exhibit Hall C
Plenary Abstract Presenter: Lakshmi Nayak – Dana-Farber Cancer Institute
Author: Caroline Falvey – DFCI
Author: Riemke Bouvier – DFCI
Author: Ugonma N. Chukwueke – Dana-Farber Cancer Institute
Author: Sarah Hogan – DFCI
Author: Elizabeth Kendricken – DFCI
Author: Christopher Meehan – DFCI
Author: Robert Redd – DFCI
Author: Jennifer Fisher – DFCI
Author: Alexandra Torres – Dana-Farber Cancer Institute
Author: Julia Jones – DFCI
Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
Author: Austin Kim – DFCI
Author: Luis Nicolas Gonzalez Castro – Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
Author: Jose Ricardo R. McFaline-Figueroa – Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
Author: Elisa Aquilanti – Dana Farber Cancer Institute
Author: Gilbert C. Youssef – Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
Author: Isabel Arrillaga-Romany – Massachusetts General Hospital
Author: Mark Murakami – Dana-Farber Cancer Institute
Author: Lynette Sholl – Brigham and Women's Hospital
Author: David M. Meredith – Brigham and Women's Hospital
Author: Raymond Y. Y. Huang, MD PhD – Division of Neuroradiology, Brigham and Women's Hospital and Harvard Medical School
Author: Linda Ramsdell – DFCI
Author: Ulrike Gerdemann – Boston Children's Hospital/ DFCI
Author: Paula Keskula – Boston Children's Hospital/ DFCI
Author: Jim Kaminski – Boston Children's Hospital/ DFCI
Author: Alexandre Albanese – DFCI
Author: Wenya Linda Bi – Department of Neurosurgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA
Author: Omar Arnaout – Department of Neurosurgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA
Author: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Patrick Y. Wen – Dana-Farber Cancer Institute
Author: Soumya Poddar – Kite
Author: Daqin Mao – Kite
Author: Mike Mattie – Kite
Author: Madison Davis – Kite
Author: Simone Filosto – Kite
Author: Leslie Kean – Boston Children's Hospital/ DFCI
Author: Philippe Armand – DFCI
Author: Caron Jacobson – DFCI
Clinical trials: Immunologic
Friday, Nov 17th
8:02 PM – 8:06 PM PT
CTIM-24 - Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab remodels the tumor microenvironment in de novo glioblastoma
Location: Exhibit Hall A/B
Rapid and Poster Presenter: Zev A. Binder – University of Pennsylvania
Author: Stephen J. Bagley – University of Pennsylvania
Author: Lamia Lamrani – Institut Curie
Author: Eliana Marinari – Universite de Geneve
Author: Arati S. Desai – University of Pennsylvania
Author: MacLean P. Nasrallah – University of Pennsylvania, USA
Author: Eileen Maloney – University of Pennsylvania
Author: Steven Brem – University of Pennsylvania
Author: Robert A A. Lustig – University of Pennsylvania
Author: Goldie Kurtz – University of Pennsylvania
Author: Michelle Alonso-Basanta – University of Pennsylvania
Author: Pierre-Emmanuel Bonte – Institut Curie
Author: Christel Goudot – Institut Curie
Author: Wilfrid Richer – Institut Curie
Author: Eliane Piaggio – Institut Curie
Author: Shawn Kothari – Emory University
Author: Lea Guyonnet – Institut Curie
Author: Coralie Guerin – Institut Curie
Author: Joshua Waterfall – Institut Curie
Author: Suyash Mohan – University of Pennsylvania
Author: Wei-Ting Hwang – University of Pennsylvania
Author: Oliver Y. Tang – Brown University
Author: Meghan Logun – University of Pennsylvania
Author: Meghna Bhattacharyya – Rowan University
Author: Kelly Markowitz – University of Pennsylvania
Author: Devora Delman – University of Pennsylvania
Author: Amy Marshall – University of Pennsylvania
Author: E. John J. Wherry – University of Pennsylvania
Author: Sebastian Amigorena – Institut Curie
Author: Gregory Beatty – University of Pennsylvania
Author: Jennifer Brogdon – Novartis Institutes for BioMedical Research
Author: Elizabeth Hexner – University of Pennsylvania
Author: Denis Migliorini – Universite de Geneve
Author: Cecile Alanio – Institut Curie
Author: Donald M M. O'Rourke – University of Pennsylvania
Clinical trials: Immunologic
Friday, Nov 17th
8:06 PM – 8:10 PM PT
CTIM-29 - Final efficacy and correlative analyses of 2-THE-TOP: A pilot study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide in patients with newly diagnosed glioblastoma (ndGBM)
Location: Exhibit Hall A/B
Rapid and Poster Presenter: David D. Tran – University of Southern California Department of Neurological Surgery
Author: Dongjiang Chen – University of Southern California Department of Neurological Surgery
Author: Son B. Le – University of Southern California Department of Neurological Surgery
Author: Ashley P. Ghiaseddin – University of Florida
Clinical trials: Immunologic
Friday, Nov 17th
8:18 PM – 8:22 PM PT
CTIM-16 - Developing patient specific tumor infiltrating lymphocytes (TILs) with increased tumor specificity as a therapy for glioblastoma
Location: Exhibit Hall A/B
Rapid and Poster Presenter: Kelly M. Hotchkiss – Duke University
Author: Emily Blandford – Duke University
Author: Pamela Noldner – Marcus Center for Cellular Cures
Author: Ying Zhou – Marcus Center for Cellular Cures
Author: Kirit Singh – Duke Brain Tumor Immunotherapy Program
Author: Anoop Patel – Department of Neurosurgery, Duke University
Author: Peter E. Fecci – Duke University Department of Neurosurgery
Author: Scott Antonia – Duke University
Author: Beth Shaz – Marcus Center for Cellular Cures
Author: Mustafa Khasraw – Duke Cancer Institute
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-01 - Nivolumab and stereotactic radiosurgery (SRS) for patients with breast cancer brain metastases: long term results and cell free DNA (cfDNA) assessment from a non-randomized, open-label, phase Ib study
Location: Exhibit Hall A/B
Poster Presenter: Kamran A. Ahmed – H. Lee Moffitt Cancer Center & Research Institute
Author: Youngchul Kim, FLORIDA – Moffitt Cancer Center
Author: John Arrington – Moffitt Cancer Center
Author: Sungjune Kim – Moffitt Cancer Center
Author: Michelle DeJesus – Moffitt Cancer Center
Author: Aixa Soyano – Moffitt Cancer Center
Author: Avan Armaghani – Moffitt Cancer Center
Author: Ricardo Costa – Moffitt Cancer Center
Author: Hung Khong – Moffitt Cancer Center
Author: Loretta Loftus – Moffitt Cancer Center
Author: Marilin Rosa – Moffitt Cancer Center
Author: Jimmy Caudell – Moffitt Cancer Center
Author: Roberto Diaz – Moffitt Cancer Center
Author: Arnold B. Etame – Moffitt Cancer Center
Author: Nam D. Tran – Moffitt Cancer Center
Author: Hatem Soliman – Moffitt Cancer Center
Author: Brian Czerniecki – Moffitt Cancer Center
Author: Peter Forsyth – Moffitt Cancer Center
Author: Hsiang-Hsuan Michael Yu – H. Lee Moffitt Cancer Center & Research Institute
Author: Hyo Han – Moffitt Cancer Center
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-03 - Long term follow-up of a prospective safety and toxicity study of immune checkpoint inhibitor therapy initiated 8 days prior to radiosurgery for melanoma brain or spine metastasis.
Location: Exhibit Hall A/B
Poster Presenter: Lawrence Richard Kleinberg – Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Author: Xiaobu Ye – Johns Hopkins university
Author: William Sharfman – Johns Hopkins University
Author: Christopher M. Jackson – Johns Hopkins University School of Medicine
Author: Kristin Redmond – Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Author: Chetan Bettegowda – Johns Hopkins Medical Institutes
Author: Kelly Szajna – Johns Hopkins University
Author: Whitney Isennock – Johns Hopkins University
Author: Jessica Wollett – Johns Hopkins University
Author: Evan Lipson – Johns Hopkins University
Author: Michael Lim – Stanford University School of Medicine
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-04 - Topical Diphencyprone Immunotherapy for Cutaneous Neurofibromas Associated with NF1, A Phase 1 Study
Location: Exhibit Hall A/B
Poster Presenter: Rebecca M. Brown – The Icahn School of Medicine at Mount Sinai
Author: Nicholas Gulati – The Icahn School of Medicine at Mount Sinai
Author: Dina Poplauski – The Mount Sinai Hospital
Author: Jade Young – The Mount Sinai Hospital
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-05 - Results of safety lead in of phase II trial of combination olaparib, temozolomide, and pembrolizumab for patients with IDH-mutant glioma
Location: Exhibit Hall A/B
Poster Presenter: John T. Fortunato – Memorial Sloan Kettering Cancer Center
Author: Adam Newton – Memorial Sloan Kettering Cancer Center
Author: Ashley Gonzalez – Memorial Sloan Kettering Cancer Center
Author: Igor Gavrilovic – Memorial Sloan Kettering Cancer Center
Author: Alexandra M. Miller – Memorial Sloan Kettering Cancer Center
Author: Christian Grommes – Memorial Sloan Kettering Cancer Center
Author: Andrew L. Lin – Memorial Sloan Kettering Cancer Center
Author: Elena Pentsova – Memorial Sloan Kettering Cancer Center
Author: Ingo K. Mellinghoff – Memorial Sloan Kettering Cancer Center
Author: Thomas Kaley – Memorial Sloan Kettering Cancer Center
Author: Lauren R. Schaff – Memorial Sloan Kettering Cancer Center
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-10 - A surgical window-of-opportunity clinical trial evaluating the PCSK9 inhibitor Evolocumab in patients with glioma
Location: Exhibit Hall A/B
Author: Kirit Singh – Duke Brain Tumor Immunotherapy Program
Poster Presenter: Kelly M. Hotchkiss – Duke University
Author: Matthew W. Foster – Duke Proteomics and Metabolomics core
Author: Chelsea Railton – Duke Brain Tumor Immunotherapy Program
Author: Emily Blandford – Duke University
Author: Elizabeth Thomas – Duke University Brain Tumor Biorepository
Author: Elizabeth S. S. Miller – Duke University School of Medicine, The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
Author: David M. Ashley – The Preston Robert Tisch Brain Tumor Center
Author: Annick Desjardins – Duke University
Author: Henry S. Friedman – The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
Author: Margaret O. O. Johnson – Duke University School of Medicine, The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery
Author: Allan H. Friedman – Department of Neurosurgery, Duke University
Author: Steve T. Keir – Duke University School of Medicine
Author: James E. Herndon, II – Duke Cancer Institute, Department of Biostatistics
Author: John H. Sampson – Duke University
Author: Chuan-Yuan Li – Duke Cancer Institute
Author: Peter E. Fecci – Duke University Department of Neurosurgery
Author: Anoop Patel – Department of Neurosurgery, Duke University
Author: Mustafa Khasraw – Duke Cancer Institute
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-12 - Immunogenicity of an additional dose of Covid-19 vaccine in fully vaccinated patients with glioma to evaluate new national vaccination guidelines - a prospective cohort study
Location: Exhibit Hall A/B
Poster Presenter: Teresa Schmidt – Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Hana Rohn – Department of Infection Diseases, West German Centre of Infection Diseases, University Hospital Essen, Essen, Germany
Author: Mirko Trilling – Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Author: Sarina Agkatsev – Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Christoph Oster – Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Christoph Kleinschnitz – Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Ulrich Sure – Department of Neurosurgery and Spine Surgery, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Martin Stuschke – Department of Radiotherapy, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Björn Scheffler – German Cancer Research Center (DKFZ), Heidelberg, Germany
Author: Sied Kebir – Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Author: Martin Glas – Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Germany
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-15 - T cell Response Dynamics in Phase 3 Glioblastoma Patients Immunized with Autologous Dendritic Cells pulsed with Autologous Tumor Cell Lysate
Location: Exhibit Hall A/B
Poster Presenter: Marnix Bosch – Northwest Biotherapeutics, inc
Author: Linda M. Liau – UCLA
Author: Keyoumars Ashkan – Kings College Hospital
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-16 - Developing patient specific tumor infiltrating lymphocytes (TILs) with increased tumor specificity as a therapy for glioblastoma
Location: Exhibit Hall A/B
Poster Presenter: Kelly M. Hotchkiss – Duke University
Author: Emily Blandford – Duke University
Author: Pamela Noldner – Marcus Center for Cellular Cures
Author: Ying Zhou – Marcus Center for Cellular Cures
Author: Kirit Singh – Duke Brain Tumor Immunotherapy Program
Author: Anoop Patel – Department of Neurosurgery, Duke University
Author: Peter E. Fecci – Duke University Department of Neurosurgery
Author: Scott Antonia – Duke University
Author: Beth Shaz – Marcus Center for Cellular Cures
Author: Mustafa Khasraw – Duke Cancer Institute
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-17 - Additional results from a phase 1b study of IGV-001 in patients with newly diagnosed glioblastoma.
Location: Exhibit Hall A/B
Poster Presenter: Raul Perez-Olle – Imvax, Inc.
Author: Gregory Pennock – Imvax, Inc.
Author: Charles Scott – Imvax, Inc.
Author: D. Craig Hooper – Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University
Author: Kevin D. Judy – Thomas Jefferson University
Author: David W. Andrews – Imvax, Inc.
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-21 - T-cell receptor repertoire analysis in PBMCs from pediatric patients with recurrent medulloblastoma during adoptive cellular therapy
Location: Exhibit Hall A/B
Poster Presenter: Oleg Yegorov – University of Florida
Author: Changlin Yang – University of Florida
Author: Yanina Yegorova – University of Florida
Author: Duane A. Mitchell – University of Florida
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-24 - Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab remodels the tumor microenvironment in de novo glioblastoma
Location: Exhibit Hall A/B
Poster Presenter: Zev A. Binder – University of Pennsylvania
Author: Stephen J. Bagley – University of Pennsylvania
Author: Lamia Lamrani – Institut Curie
Author: Eliana Marinari – Universite de Geneve
Author: Arati S. Desai – University of Pennsylvania
Author: MacLean P. Nasrallah – University of Pennsylvania, USA
Author: Eileen Maloney – University of Pennsylvania
Author: Steven Brem – University of Pennsylvania
Author: Robert A A. Lustig – University of Pennsylvania
Author: Goldie Kurtz – University of Pennsylvania
Author: Michelle Alonso-Basanta – University of Pennsylvania
Author: Pierre-Emmanuel Bonte – Institut Curie
Author: Christel Goudot – Institut Curie
Author: Wilfrid Richer – Institut Curie
Author: Eliane Piaggio – Institut Curie
Author: Shawn Kothari – Emory University
Author: Lea Guyonnet – Institut Curie
Author: Coralie Guerin – Institut Curie
Author: Joshua Waterfall – Institut Curie
Author: Suyash Mohan – University of Pennsylvania
Author: Wei-Ting Hwang – University of Pennsylvania
Author: Oliver Y. Tang – Brown University
Author: Meghan Logun – University of Pennsylvania
Author: Meghna Bhattacharyya – Rowan University
Author: Kelly Markowitz – University of Pennsylvania
Author: Devora Delman – University of Pennsylvania
Author: Amy Marshall – University of Pennsylvania
Author: E. John J. Wherry – University of Pennsylvania
Author: Sebastian Amigorena – Institut Curie
Author: Gregory Beatty – University of Pennsylvania
Author: Jennifer Brogdon – Novartis Institutes for BioMedical Research
Author: Elizabeth Hexner – University of Pennsylvania
Author: Denis Migliorini – Universite de Geneve
Author: Cecile Alanio – Institut Curie
Author: Donald M M. O'Rourke – University of Pennsylvania
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-27 - Peripheral Biomarker Analysis of T cell-mediated Collagen Remodeling Correlates with Tumor Responses in a Phase IIa trial of vaccine immunotherapeutic candidate (VBI-1901)
Location: Exhibit Hall A/B
Poster Presenter: Fabio M. Iwamoto – Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center
Author: Neel Nissen – Nordic Bioscience
Author: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Deborah A. Forst – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
Author: Tamara Berthoud – VBI Vaccines Inc.
Author: Catalina Soare – VBI Vaccines Inc.
Author: Francisco Diaz-Mitoma – VBI Vaccines Inc.
Author: David E. Anderson – VBI Vaccines Inc.
Author: Patrick Y. Wen – Dana-Farber Cancer Institute
Author: Nicholas Willumsen – Nordic Bioscience
Author: Morten Karsdal – Nordic Bioscience
Author: Andrew B. Lassman – Columbia University Vagelos College of Physicians and Surgeons and New York Presbyterian Hospital
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-28 - First-in-human transgene detection 17 months post-adenoviral therapy
Location: Exhibit Hall A/B
Poster Presenter: Maria Luisa Varela – University of Michigan Medical School
Author: Molly E. J. West – University of Michigan Medical School
Author: Syed M. M. Faisal – University of Michigan Medical School
Author: Andrea Comba – University of Michigan Medical School
Author: Maria G. Castro – University of Michigan Medical School
Author: Pedro R. Lowenstein – Department of Neurosurgery, and Cell and Developmental Biology, Rogel Cancer Center, University of Michigan Medical School
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-29 - Final efficacy and correlative analyses of 2-THE-TOP: A pilot study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide in patients with newly diagnosed glioblastoma (ndGBM)
Location: Exhibit Hall A/B
Poster Presenter: David D. Tran – University of Southern California Department of Neurological Surgery
Author: Dongjiang Chen – University of Southern California Department of Neurological Surgery
Author: Son B. Le – University of Southern California Department of Neurological Surgery
Author: Ashley P. Ghiaseddin – University of Florida
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-30 - A Phase 1b, open-label, dose-escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T cell engager, BI 764532, in patients with DLL3-positive glioma
Location: Exhibit Hall A/B
Poster Presenter: Martin J. van den Bent – Erasmus MC Cancer Institute
Author: Patrick Roth – Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
Author: Ghazaleh Tabatabai – University Hospital Tübingen and Eberhard Karls University Tübingen
Author: Michael C. Burger – Dr Senckenberg Institute of Neurooncology, Goethe University Hospital
Author: Maria Martinez-Garcia – Department of Medical Oncology, Hospital del Mar-CIBERONC
Author: Louisa von Baumgarten – Dept. of Neurosurgery, Ludwig Maximilians University (LMU) Munich,
Author: Richard Greil – IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT); Cancer Cluster Salzburg
Author: Matus Studeny – Boehringer Ingelheim International GmbH
Author: Monika Simetzberger – Boehringer Ingelheim RCV GmbH & Co KG
Author: Meiruo Liu – Boehringer Ingelheim (China) Investment Co. Ltd, Biostatistics and Data Sciences
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-31 - Clinical Impact of adding Pembrolizumab to standard of care chemoradiation in patients with newly diagnosed glioblastoma
Location: Exhibit Hall A/B
Poster Presenter: Prakash Ambady – Providence Health Center
Author: Ramon F. Barajas, Jr. – Oregon Health and Science University
Author: Rochelle Fu – Oregon Health & Science University
Author: Laszlo szidonya – Oregon Health & Science University
Author: Amy Huddleston – Oregon Health & Science University
Author: lauren popp – Providence Health and Services
Author: Dana Moussalli – Providence Health and Services
Author: Maria Turchan – Providence Health and Services
Author: claire Diaz – Oregon Health & Science University
Author: Neuwelt Edward – Oregon Health & Science University
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-32 - A parallel cohort phase 2 study of regorafenib plus nivolumab for recurrent or metastatic solid tumors: results in patients with glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)
Location: Exhibit Hall A/B
Author: Matteo Simonelli – Oncology Department, IRCCS Humanitas Research Hospital
Author: Mario Caccese – Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS
Author: Delphine Larrieu-Ciron – Department of Neurology, Toulouse University Hospital
Author: Enrico Franceschi – Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna
Author: Tae Min Kim – Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Author: Jerome Fayette – Centre Léon Bérard
Author: Pierre Freres – Department of Medical Oncology, University Hospital of Liège, CHU Sart Tilman
Author: Marie Robert – Department of Medical Oncology, Institut de Cancérologie de l'Ouest
Author: Marica Eoli – Fondazione IRCCS Carlo Besta
Author: Sylvie Luce – Department of Oncology, Hôpital Erasme, Université Libre de Bruxelles
Author: Jana L. Portnow – Department of Medical Oncology, City of Hope Beckman Research Institute
Author: Yuki Hirata – Ono Pharmaceutical Co., Ltd
Author: Kengo Enya – Ono Pharmaceutical Co., Ltd
Author: Ian Waxman – Bristol-Myers Squibb
Author: Lixian Jin – Bristol-Myers Squibb
Author: Dipam Shah – Bayer HealthCare Pharmaceuticals
Author: Uta Drews – Bayer AG
Author: Marie-Aude Le Berre – Bayer HealthCare SAS
Poster Presenter: Giuseppe Lombardi – Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-33 - Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma
Location: Exhibit Hall A/B
Author: Mason J. Webb – Mayo Clinic
Poster Presenter: Ugur T. Sener – Mayo Clinic
Author: Terry C. Burns – Mayo Clinic Rochester
Author: Erin Twohy – Mayo Clinic
Author: Sani H. Kizilbash – Mayo Clinic (Rochester)
Author: Michael W. Ruff – Mayo Clinic
Author: Joon H. Uhm – Mayo Clinic
Author: Evanthia Galanis – Mayo Clinic
Author: Stacy D'Andre – Mayo Clinic
Author: Cecile Riviere-Cazaux – Mayo Clinic
Author: Byung Ha Lee – NeoImmuneTech Inc.
Author: Lynn Flickinger – Mayo Clinic
Author: Ian F. Parney – Mayo Clinic
Author: Jian L. Campian – Mayo Clinic
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-34 - JACOB: Joint Administration of cDNA for TP53, checkpOint inhibition, and Boost/Hypo fractionated radiation. A phase 0/1 study in children with recurrent, progressive, or refractory CNS malignancies
Location: Exhibit Hall A/B
Poster Presenter: Adriana Fonseca – Children's National Hospital
Author: Sang Soo Kim – George Washington University
Author: Russell Cruz – Children's National Hospital
Author: Matthew Ladra – Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital
Author: Kathleen Pirollo – George Washington University
Author: Esther Chang – George Washington University
Author: Roger Packer – Children's National Hospital
Author: Eugene Hwang – Children's National Hospital
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-35 - INB-400 Phase 1b/2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells in Combination With Maintenance Temozolomide Recurrent or Newly Diagnosed Glioblastoma
Location: Exhibit Hall A/B
Author: Trishna Goswami – IN8bio
Author: Lawrence Lamb – IN8bio
Author: Kate Rochlin – IN8bio
Poster Presenter: Burt Nabors – Heersink School of Medicine
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-36 - Immunohistochemistry evaluation on pre-treatment tumor tissue predicts treatment response to MN-166 (ibudilast) and Temozolomide combination therapy in glioblastoma patients.
Location: Exhibit Hall A/B
Poster Presenter: Justin D. Lathia – Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute
Author: Adam J. Lauko – Cleveland Clinic
Author: Kazuko matsuda – MediciNova Inc
Author: Malath Makhay – MediciNova Inc.
Author: Lakshmi Nayak – Dana-Farber Cancer Institute
Author: Ugonma N. Chukwueke – Dana-Farber Cancer Institute
Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
Author: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Rameen Beroukhim – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Tracy T. Batchelor – Brigham and Women’s Hospital Harvard Medical School
Author: Elisa Aquilanti – Dana Farber Cancer Institute
Author: Patrick Y. Wen – Dana-Farber Cancer Institute
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-38 - Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells
Location: Exhibit Hall A/B
Poster Presenter: Philipp Karschnia – Dept. of Neurosurgery, Ludwig Maximilians University (LMU) Munich,
Author: Isabel Arrillaga-Romany – Massachusetts General Hospital
Author: April F. Eichler – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Deborah A. Forst – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Elizabeth R. Gerstner – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Justin T. T. Jordan – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Ina Ly – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Scott R. Plotkin – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Nancy Wang – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Maria Martinez-Lage – Department of Pathology, Division of Neuropathology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Sebastian F. F. Winter – Dept. of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Joerg-Christian Tonn – Department of Neurosurgery, University Hospital, LMU Munich
Author: Kai Rejeski – Dept. of Medicine III - Hematology/Oncology, Ludwig Maximilians University (LMU), and German Cancer Consortium (DKTK) Partner Site,
Author: Louisa von Baumgarten – Dept. of Neurosurgery, Ludwig Maximilians University (LMU) Munich,
Author: Daniel P. Cahill – Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
Author: Brian V. Nahed – Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
Author: Ganesh M. Shankar – Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
Author: Jeremy S. Abramson – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Jeffrey A. Barnes – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Areej El-Jawahri – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Ephraim P. Hochberg – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: P. Connor C. Johnson – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Jacob D. Soumerai – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Ronald W. Takvorian – Department of Medicine, Hematology & Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Yi-Bin Chen – Department of Medicine, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Matthew J. Frigault – Department of Medicine, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Jorg Dietrich – Dept. of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-40 - Early radiographic response and engraftment of Phase I first-in-human bicistronic CAR T cells correlate with real-time autologous GBM organoid cytolysis.
Location: Exhibit Hall A/B
Poster Presenter: Meghan Logun – University of Pennsylvania
Author: Stephen J. Bagley – University of Pennsylvania
Author: Xin Wang – University of Pennsylvania
Author: Daniel Zhang – University of Pennsylvania
Author: Yusha Sun – University of Pennsylvania
Author: Guo-li Ming – University of Pennsylvania
Author: Ali Nabavizadeh – University of Pennsylvania
Author: Amy Marshall – University of Pennsylvania
Author: Eileen Maloney – University of Pennsylvania
Author: Wei-Ting Hwang – University of Pennsylvania
Author: Joseph Fraietta – University of Pennsylvania
Author: Vanessa Gonzalez – University of Pennsylvania
Author: Arati S. Desai – University of Pennsylvania
Author: Linda Bagley – University of Pennsylvania
Author: Elizabeth Hexner – University of Pennsylvania
Author: MacLean P. Nasrallah – University of Pennsylvania, USA
Author: Hongjun Song – University of Pennsylvania
Author: Zev A. Binder – University of Pennsylvania
Author: Donald M M. O'Rourke – University of Pennsylvania
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-41 - Oncolytic immunotherapy links immunoactivation to subject survival in phase I trial of recurrent glioblastoma
Location: Exhibit Hall A/B
Poster Presenter: Alexander L. Ling – Brigham and Women's Hospital
Author: Isaac H. Solomon – Brigham and Women's Hospital
Author: Hiroshi Nakashima – Brigham and Women's Hospital/ Harvard Medical School
Author: Andres Santos – Brigham and Women's Hospital
Author: Francesca Barone – Candel Therapeutics
Author: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: E. Antonio Chiocca – Brigham and Women's Hospital/ Harvard Medical School
Clinical trials: Immunologic
Friday, Nov 17th
7:30 PM – 9:30 PM PT
CTIM-42 - INB-200: Phase 1 Study of Gene Modified Autologous Gamma-delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance Temozolomide (TMZ)
Location: Exhibit Hall A/B
Poster Presenter: Mina Lobbous – Cleveland Clinic Case Western Reserve University
Author: Trishna Goswami – IN8bio
Author: Lawrence Lamb – IN8bio
Author: Kate Rochlin – IN8bio
Author: Thiumaine Pillay – UAB
Author: samantha Youngblood – In8bio
Author: Mariska ter Haak – IN8bio
Author: Burt Nabors – Heersink School of Medicine
Clinical trials: Immunologic
Saturday, Nov 18th
10:55 AM – 11:05 AM PT
CTIM-02 - Phase 2 trial of pembrolizumab for patients with brain metastases of diverse histologies
Location: Room 109-110
Oral Abstract Presenter: Priscilla K. Brastianos – Massachusetts General Hospital/Harvard Medical School
Author: Albert Kim – Department of Neurology, Massachusetts General hospital, Boston, MA
Author: Anita Giobbe-Hurder – Dana-Farber Cancer Institute
Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
Author: Nancy Lin – Dana-Farber Cancer Institute
Author: Beth Overmoyer – Dana-Farber Cancer Institute
Author: Patrick Y. Wen – Dana-Farber Cancer Institute
Author: Lakshmi Nayak – Dana-Farber Cancer Institute
Author: Justine Cohen – University of Pennsylvania
Author: Jorg Dietrich – Dept. of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: April F. Eichler – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Rebecca Heist – Massachusetts General Hospital/Harvard Medical School
Author: Ian Krop – Yale School of Medicine
Author: Donald Lawrence – Massachusetts General Hospital/Harvard Medical School
Author: Jennifer Ligibel – Dana-Farber Cancer Institute
Author: Sara Tolaney – Dana-Farber Cancer Institute
Author: Erica Mayer – Dana-Farber Cancer Institute
Author: Eric Winer – Yale School of Medicine
Author: Brittany Bent – Massachusetts General Hospital/Harvard Medical School
Author: Magali De Sauvage – Massachusetts General Hospital
Author: Nazanin Ijad – Massachusetts General Hospital
Author: Juliana Larson – Massachusetts General Hospital/Harvard Medical School
Author: Braxton Marion – Massachusetts General Hospital/Harvard Medical School
Author: Sally Nason – Dana-Farber Cancer Institute
Author: Naina Murthy – Massachusetts General Hospital/Harvard Medical School
Author: Elizabeth J. Summers – Massachusetts General Hospital
Author: Sherry Ratcliffe – Dana-Farber Cancer Institute
Author: Maura Mahar – Massachusetts General Hospital/Harvard Medical School
Author: Helen A. Shih – Massachusetts General Hospital/Harvard Medical School
Author: Kevin Oh – Massachusetts General Hospital/Harvard Medical School
Author: Daniel P. Cahill – Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School
Author: Elizabeth R. Gerstner – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: Ryan J. Sullivan – Massachusetts General Hospital/Harvard Medical School
Clinical trials: Immunologic
Saturday, Nov 18th
4:55 PM – 5:00 PM PT
CTIM-39 - A Phase 1b study of pembrolizumab, ibrutinib and rituximab in recurrent/refractory (RR) primary central nervous system lymphoma (PCNSL)
Location: Room 121-122
Oral Abstract Presenter: Ugonma N. Chukwueke – Dana-Farber Cancer Institute
Author: Isobel Wright – Dana-Farber Cancer Institute
Author: Alona Muzikansky, MA – Massachusetts General Hospital
Author: Alyssa Russ – Dana-Farber Cancer Institute
Author: Brittney Fontana – Dana-Farber Cancer Institute
Author: Vanessa Kats – Dana-Farber Cancer Institute
Author: Colin O'Donnell – Dana_Farber Cancer Institute
Author: Renee Scalfani – Dana-Farber Cancer Institute
Author: Brenda Acevedo-Naranjo – Dana-Farber Cancer Institute
Author: Eudocia Q. Lee – Dana-Farber Cancer Institute, Boston, MA
Author: Luis Nicolas Gonzalez Castro – Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
Author: Jose Ricardo R. McFaline-Figueroa – Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
Author: Elisa Aquilanti – Dana Farber Cancer Institute
Author: Gilbert C. Youssef – Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
Author: Rameen Beroukhim – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Deborah A. Forst – Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Author: David A. Reardon – Center for Neuro-Oncology, Dana-Farber Cancer Institute
Author: Patrick Y. Wen – Dana-Farber Cancer Institute
Author: Tracy T. Batchelor – Brigham and Women’s Hospital Harvard Medical School
Author: Alexandra Torres – Dana-Farber Cancer Institute
Author: Jennifer Stefanik – Dana-Farber Cancer Institute
Author: Jennifer Fisher – DFCI
Author: David M. Meredith – Brigham and Women's Hospital
Author: Mark Murakami – Dana-Farber Cancer Institute
Author: Yuri Garcia – Dana-Farber Cancer Institute
Author: Margaret Shipp – Dana-Farber Cancer Institute
Author: Lakshmi Nayak – Dana-Farber Cancer Institute
Clinical trials: Immunologic